| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Tropinone does not have a well-defined primary pharmacological target as a drug itself; its biological effects are primarily related to its metabolic conversion to other tropane alkaloids. It is a substrate for tropinone reductase enzymes (EC 1.1.1.236 and EC 1.1.1.206), which reduce the ketone group to form tropine or pseudotropine. These enzymes are found in plants and some microorganisms.
|
|---|---|
| ln Vitro |
Tropinone exhibits weak or no significant direct in vitro activity in typical mammalian receptor or enzyme assays. Its primary in vitro utility is as a substrate for studying tropinone reductase activity in enzyme kinetics assays. In cell-free systems, it is used to measure reductase activity by monitoring NADPH oxidation at 340 nm. It shows no notable cytotoxicity or receptor binding affinity in standard panels.
|
| ln Vivo |
In vivo, tropinone is not a pharmacologically active agent but is metabolically converted to tropine and other derivatives. In animal models, its effects are indirect and result from its biotransformation to active tropane alkaloids. It has low acute toxicity (LD50 oral rat > 2000 mg/kg). There is no significant in vivo efficacy data as tropinone itself is not a candidate drug.
|
| Enzyme Assay |
The in vitro enzyme assay for tropinone reductase typically uses a reaction mixture containing 0.1 M phosphate buffer (pH 6.5-7.5), 1 mM tropinone, 0.2 mM NADPH, and the enzyme source (plant extract or recombinant enzyme). The reaction is initiated by adding tropinone and the decrease in absorbance at 340 nm is monitored over 5-10 minutes at 25°C. One unit of enzyme activity is defined as the amount reducing 1 μmol of NADPH per minute. Controls without substrate are essential.
|
| Cell Assay |
No standardized in vitro cellular assays are specifically designed for tropinone as a bioactive compound. It may be used in cell culture studies as a negative control or to assess cellular metabolism of tropane alkaloids. Typical concentrations for such studies range from 10 μM to 1 mM. Cell viability assays (MTT or resazurin) can be performed to confirm lack of cytotoxicity in hepatocyte or neuronal cell lines.
|
| Animal Protocol |
Tropinone is not used in in vivo animal experiments as a therapeutic agent. However, in pharmacokinetic or metabolic studies, it can be administered orally or intraperitoneally to rodents (typically 10-50 mg/kg) to study its absorption and conversion to tropine. Blood and urine samples are collected at predetermined time points and analyzed by LC-MS/MS to quantify tropinone and its metabolites.
|
| ADME/Pharmacokinetics |
There are limited published pharmacokinetic data for tropinone. In rodents, after oral administration, tropinone is rapidly absorbed and extensively metabolized, primarily to tropine. The plasma half-life is estimated to be short (1-2 hours). Bioavailability is low due to first-pass metabolism. The compound is hydrophilic (Log P ~ 0.5) and exhibits moderate plasma protein binding.
|
| Toxicity/Toxicokinetics |
Acute toxicity of tropinone is low in rodents (oral LD50 > 2000 mg/kg). It is not classified as a mutagen or carcinogen. The main toxicological concern is its status as a precursor for controlled substances. Repeated dose toxicity studies are not available. It may cause mild skin and eye irritation. No specific target organ toxicity has been identified.
|
| References | |
| Additional Infomation |
Tropicone has been reported to be found in Convolvulaceae plants, Datura stramonium, and other organisms for which data is available.
Tropinone is a scheduled chemical in many jurisdictions due to its use in the illicit synthesis of cocaine and tropane derivatives. It is a white crystalline powder with a melting point of 42-44°C. It is soluble in water, ethanol, and chloroform. In research, it is primarily used as a starting material for the synthesis of hyoscyamine, scopolamine, and other tropane alkaloids. |
| Molecular Formula |
C8H13NO
|
|---|---|
| Molecular Weight |
139.1949
|
| Exact Mass |
139.099
|
| CAS # |
532-24-1
|
| Related CAS # |
4827-85-4 (hydrochloride);74051-45-9 (hydrobromide)
|
| PubChem CID |
79038
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
217.1±0.0 °C at 760 mmHg
|
| Melting Point |
40-44 °C(lit.)
|
| Flash Point |
90.0±0.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.505
|
| LogP |
0.07
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])([H])C2([H])C([H])([H])C([H])([H])C([H])(C1([H])[H])N2C([H])([H])[H]
|
| InChi Key |
QQXLDOJGLXJCSE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H13NO/c1-9-6-2-3-7(9)5-8(10)4-6/h6-7H,2-5H2,1H3
|
| Chemical Name |
8-methyl-8-azabicyclo[3.2.1]octan-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~718.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1844 mL | 35.9221 mL | 71.8442 mL | |
| 5 mM | 1.4369 mL | 7.1844 mL | 14.3688 mL | |
| 10 mM | 0.7184 mL | 3.5922 mL | 7.1844 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
